Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 10/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.37 |
| ▸ | SGK1 | O00141 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523444 | 0.76 | MBOAT4 (0.46) | CNR1CNR2MBOAT4SGK1KDM4E | |
| SCHEMBL20782303 | 0.76 | CNR2 (0.43) | CNR1CNR2MBOAT4SGK1 | |
| SCHEMBL3288328 | 0.75 | ALDH1A1 (0.34) | CNR2SGK1KDM4EMAPT | |
| SCHEMBL3290433 | 0.72 | KHK (0.44) | KHKCNR1CNR2TRPV4KDM4E | |
| SCHEMBL29448448 | 0.71 | KHK (0.69) | KHKTRPV4KDM4ETDP1 | |
| SCHEMBL29448447 | 0.71 | KHK (0.69) | KHKTRPV4KDM4ETDP1 | |
| SCHEMBL165776 | 0.71 | KHK (0.69) | KHKTRPV4KDM4ETDP1 | |
| SCHEMBL3288183 | 0.71 | ALDH1A1 (0.43) | TRPV4KDM4EMAPT | |
| SCHEMBL3062400 | 0.70 | ALDH1A1 (0.42) | CNR1CNR2MBOAT4SGK1KDM4E | |
| SCHEMBL564801 | 0.69 | PDE4A (0.37) | KHKCNR1CNR2KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546374-B2 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-12-27 | — | — | US | disclosed |
| US-8217067-B2 | Antiinflammatory agents, antidepressants, analgesics, purinergic receptor antagonists; neurodegenerative diseases, spinal cord injuries; 1-(2,3-dichlorophenyl)-N-[(2-methylphenyl)methyl]-1H-tetraazol-5-amine | ABBOTT LABORATORIES (US) | 2012-07-10 | — | — | US | disclosed |
| US-7704997-B1 | Amino-tetrazole analogues and methods of use | ABBOTT LABORATORIES (US) | 2010-04-27 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329772-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | P2RX7, P2RX2, P2RX5 | KHK 2311/4885CNR1 98/4885CNR2 97/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | KHK 2311/4885CNR1 98/4885CNR2 97/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | KHK 2254/4885CNR1 119/4885CNR2 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.